Wall Street analyst firm Piper Jaffary has raised its target price on Inspire Pharmaceutical stock to $25.
Inspire (Nasdaq: ISPH) opened trading Monday at $19.50 but dropped 30 cents by midday.
Piper Jaffary said the price target reflects a “lower risk profile” for the stock based on positive news about Inspire’s diquafosol drug for treatment of dry eye.
Inspire: www.inspirepharm.com
